

#### CES3 Antibody (C-term) Blocking Peptide Synthetic peptide Catalog # BP9674b

### Specification

# CES3 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

#### <u>Q6UWW8</u>

# **CES3 Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 23491

Other Names Carboxylesterase 3, Liver carboxylesterase 31 homolog, CES3

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# CES3 Antibody (C-term) Blocking Peptide - Protein Information

Name CES3

Function

Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows low catalytic efficiency for hydrolysis of CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin), a prodrug for camptothecin used in cancer therapeutics.

**Cellular Location** Endoplasmic reticulum lumen.

**Tissue Location** Expressed in liver, colon and small intestine.

# CES3 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

CES3 Antibody (C-term) Blocking Peptide - Images



### CES3 Antibody (C-term) Blocking Peptide - Background

Carboxylesterase 3 is a member of a large multigene family. The enzymes encoded by these genes are responsible for the hydrolysis of ester- and amide-bond-containing drugs such as cocaine and heroin. They also hydrolize long-chain fatty acid esters and thioesters. The specific function of this enzyme has not yet been determined; however, it is speculated that carboxylesterases may play a role in lipid metabolism and/or the blood-brain barrier system.

#### CES3 Antibody (C-term) Blocking Peptide - References

Sanghani, S.P., et al. Protein Pept. Lett. 16(10):1207-1214(2009) Fukami, T., et al. Pharmacogenet. Genomics 18(10):911-920(2008) Sanghani, S.P., et al. Drug Metab. Dispos. 32(5):505-511(2004) Sanghani, S.P., et al. Clin. Cancer Res. 9(13):4983-4991(2003)